Novavax (NVAX) Gets a Sell From J.P. Morgan
J.P. Morgan Maintains Novavax(NVAX.US) With Sell Rating, Raises Target Price to $9
Novavax Analyst Ratings
B. Riley Adjusts Price Target on Novavax to $23 From $25, Maintains Buy Rating
Analysts Offer Insights on Healthcare Companies: Novavax (NVAX), Regulus (RGLS) and Canopy Growth (CGC)
Novavax Poised for U.S. Market Capture and Cost Efficiency Gains: A Resounding Buy Rating
Novavax (NVAX) Receives a Hold From Bank of America Securities
Novavax: Strategic Shifts and Cost-Cutting Amidst Market Uncertainty Prompt Hold Rating
Novavax Analyst Ratings
B. Riley Adjusts Price Target on Novavax to $25 From $29, Maintain Buy Rating
B.Riley Financial Maintains Novavax(NVAX.US) With Buy Rating, Cuts Target Price to $25
Buy Rating for Novavax Amid Anticipated Success of COVID-Influenza Program and Market Positioning
Novavax Price Target Announced at $8.00/Share by JP Morgan
Novavax Analyst Ratings
Novavax's Promising Outlook: Strong Market Positioning and Strategic Partnerships Fuel Buy Rating
Does Novavax's (NASDAQ:NVAX) Pullback Could Signal a Buying Opportunity
B of A Securities Maintains Neutral on Novavax, Raises Price Target to $18
Novavax Analyst Ratings
Novavax Analyst Ratings
Novavax (NVAX) Was Upgraded to a Hold Rating at J.P. Morgan